<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844931</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0089</org_study_id>
    <nct_id>NCT04844931</nct_id>
  </id_info>
  <brief_title>Remote Ischemic Conditioning With Local Ischemic Postconditioning in High-Risk ST-elevation Myocardial Infarction</brief_title>
  <acronym>RIP-HIGH</acronym>
  <official_title>Randomized Comparison of Combined Remote Ischemic Conditioning and Local Postconditioning Compared to Standard Treatment in High-risk ST-elevation Myocardial Infarction Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leipzig Heart Institute GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart Center Leipzig - University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leipzig Heart Institute GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RIP-HIGH trial is a two-arm randomized controlled trial aiming to compare the impact of&#xD;
      combined remote ischemic conditioning (RIP) and local ischemic postconditioning (PostC) vs.&#xD;
      standard of care on clinical outcome in high-risk ST-elevation myocardial infarction patients&#xD;
      undergoing primary percutaneous coronary intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary reperfusion by percutaneous coronary intervention is mandatory to salvage ischemic&#xD;
      myocardium and to reduce definite infarct size. However, reperfusion itself also causes&#xD;
      irreversible myocardial damage - a phenomenon described as reperfusion injury. Reduction of&#xD;
      ischemic and reperfusion injury by ischemic conditioning has been identified as a potential&#xD;
      target to reduce myocardial damage.&#xD;
&#xD;
      Remote ischemic conditioning and local ischemic postconditioning might be in particular of&#xD;
      clinical benefit in higher risk STEMI patients with Killip class ≥2, where mortality rates&#xD;
      are high.&#xD;
&#xD;
      The Remote Ischemic Conditioning with Local Ischemic Postconditioning in High-Risk&#xD;
      ST-elevation myocardial infarction patients (RIP-HIGH) trial is a two-arm randomized&#xD;
      controlled trial aiming to compare the impact of combined remote ischemic conditioning and&#xD;
      local ischemic postconditioning vs. standard of care on clinical outcome in high-risk&#xD;
      ST-elevation myocardial infarction patients undergoing primary percutaneous coronary&#xD;
      intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>patients will be randomized to one of the two groups in a 1:1 ratio stratified by center</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of all-cause mortality or hospitalization for heart failure (HF) within 12 months after randomization.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause mortality, HF hospitalization and survived out-of-hospital cardiac arrest at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality at 12 months.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enzymatic infarct size defined as high-sensitivity cardiac troponin T (hs-TnT) levels 72 h after randomization</measure>
    <time_frame>day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N-terminal pro B-type natriuretic peptide (NT-proBNP) levels during admission and 72 h after randomization</measure>
    <time_frame>day 0, day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis in myocardial infarction (TIMI)-flow grade of the culprit vessel post PCI</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients showing complete (≥70%) resolution of ST-segment elevation 60 minutes after reperfusion</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR-derived infarct size.</measure>
    <time_frame>day 2-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR-derived myocardial salvage index</measure>
    <time_frame>day 2-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of CMR-derived late microvascular obstruction on day 2-5 after randomization</measure>
    <time_frame>day 2-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality, HF hospitalization and survived out-of-hospital cardiac arrest assessed at 5 years via telephone contact.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>RIC + PostC in addition to standard treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery in addition to standard treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RIC + PostC + Standard PCI</intervention_name>
    <description>RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery</description>
    <arm_group_label>RIC + PostC in addition to standard treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard PCI</intervention_name>
    <description>Standard PCI</description>
    <arm_group_label>Standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute chest pain lasting &lt;12 h&#xD;
&#xD;
          -  ST-elevation at the J-point in two contiguous leads of ≥2 mm in men ≥40 years, ≥2.5 mm&#xD;
             in men &lt;40 years and ≥1.5 mm in women (regardless of age) in V2-V3 and/or ≥1 mm in all&#xD;
             other leads (52).&#xD;
&#xD;
          -  New or presumed new left bundle branch block or right bundle branch block.&#xD;
&#xD;
          -  Killip class ≥II on hospital admission or requirement of diuretics because of clinical&#xD;
             congestion.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Killip class I on hospital admission.&#xD;
&#xD;
          -  Prior fibrinolysis.&#xD;
&#xD;
          -  Conditions precluding use of RIC (i.e. paresis of the upper limb, presence of an&#xD;
             arteriovenous shunt).&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Age &lt;18 years.&#xD;
&#xD;
          -  Severe co-morbidity with a life expectancy &lt;6 months.&#xD;
&#xD;
          -  Participation in another trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holger Thiele, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Center Leipzig at University of Leipzig, Department of Internal Medicine/Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holger Thiele, Prof. Dr.</last_name>
    <phone>+49 341 865 1428</phone>
    <email>holger.thiele@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hans-Josef Feistritzer, Dr. med.</last_name>
    <phone>+49 341 865 1428</phone>
    <email>hans-josef.feistritzer@medizin.uni-leipzig.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Center Leipzig at University of Leipzig, Department of Internal Medicine/Cardiology</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Thiele, Prof. Dr.</last_name>
      <phone>+49 341 865 1428</phone>
      <email>holger.thiele@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Hans-Josef Feistritzer, Dr. med.</last_name>
      <phone>+49 341 865 1428</phone>
      <email>hans-josef.feistritzer@medizin.uni-leipzig.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>remote ischemic conditioning</keyword>
  <keyword>local ischemic postconditioning</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

